Summit Therapeutics has announced the initiation and opening of clinical trial sites for SMT112-216 (NCT07877194), a randomized, open-label, multiregional Phase II trial evaluating ivonescimab-based regimens in previously untreated advanced clear cell renal cell carcinoma (ccRCC) with sites active in the United States (US) and China. The study is being conducted in collaboration with Akeso Inc., […]
The U.S. Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) on September 24, 2026, for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) whose disease has progressed following treatment with a PD-1 or PD-L1 inhibitor. The approval was supported by data […]
GLP-1 agonists in mRCC patients showed 51% lower mortality and reduced immune toxicity with checkpoint inhibitors in 994-patient analysis.
68Ga-NY104 PET/CT shows better diagnostic efficacy than 18F-FDG PET/CT in patients with metastatic clear cell renal cell carcinoma.